Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Policy / Regulatory

China’s 8th Volume-Based Procurement Round Begins Drug Info Filing

Fineline Cube Feb 20, 2023

The national drug alliance procurement office has released a notification initiating the drug information filing...

Company Drug

BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101

Fineline Cube Feb 20, 2023

Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major....

Company Drug

Immuno Cure BioTech Launches Phase I HIV/AIDS Vaccine Study

Fineline Cube Feb 20, 2023

China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for...

Company Deals

Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China

Fineline Cube Feb 20, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for...

Company Deals

Hainan Honz Partners with GPI for Pediatric and Maternity Medicine Expansion

Fineline Cube Feb 20, 2023

China-based Hainan Honz Pharmaceutical Co., Ltd (SHE: 300086) has entered into a three-year partnership with...

Company Deals R&D

MoleculeMind Raises Over RMB 100 Million for AI Protein Design Platform

Fineline Cube Feb 20, 2023

MoleculeMind, an artificial intelligence (AI)-empowered protein design platform based in Beijing, has reportedly raised over...

Drug Policy / Regulatory

Zhejiang Suspends Generic Nesina Trading Due to IP Disputes

Fineline Cube Feb 20, 2023

Zhejiang’s Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the...

Policy / Regulatory

China’s 2022 Western Medicine Trade Analysis: Growth and Challenges

Fineline Cube Feb 20, 2023

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Drug

Wuhan Binhui’s Oncolytic Virus Therapy Awarded Breakthrough Designation by CDE

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Wuhan Binhui Biotechnology Co., Ltd’s...

Company Drug

CDE Awards Priority Review to Eisai’s Lecanemab for Early Alzheimer’s Disease

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that Japan-based Eisai’s (TYO: 4523) lecanemab has...

Company Deals Medical Device

Chunlizhengda to Acquire Majority Stake in Surgimaster for Medical Power Tools

Fineline Cube Feb 20, 2023

Beijing Chunlizhengda Medical Instruments Co., Ltd (HKG: 1858, SHA: 688236) is poised to acquire a...

Company Deals

Duoning Biotech Secures Global Rights to Junzhen’s Cell Counter Products

Fineline Cube Feb 20, 2023

China’s Shanghai Duoning Biotechnology Co., Ltd has entered into a licensing deal with compatriot firm...

Company Deals

Sansure Biotech Partners with Hunan Normal University for Research and Talent Development

Fineline Cube Feb 18, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with...

Company Deals

Amcor Acquires Shanghai-Based MDK to Expand Asia-Pacific Footprint

Fineline Cube Feb 18, 2023

Switzerland-based packaging firm Amcor (NYSE: AMCR) has unveiled the signing of a deal to acquire...

Company Drug

CSPC’s NBL-020 Gets NMPA Approval for Clinical Study in Advanced Solid Tumors

Fineline Cube Feb 17, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National...

Company Drug

Kelun Pharma’s Generic Jardiance Gains New Indication in China

Fineline Cube Feb 17, 2023

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China...

Policy / Regulatory

Hangzhou Singclean Stripped of VBP Status for Artificial Lenses

Fineline Cube Feb 17, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has revealed that Hangzhou Singclean Medical Products Co., Ltd...

Company Deals R&D

Topgen Biopharm Partners with Fudan University for Breast Cancer Gene Detection

Fineline Cube Feb 17, 2023

Zhejiang-based tumor precision medicine specialist Topgen Biopharm Co., Ltd has entered into a strategic partnership...

Company Deals Digital

By-Health Partners with Meituan’s Drug Purchase APP for New Retail Expansion

Fineline Cube Feb 17, 2023

China-based By-Health Co., Ltd. (SHE: 300146) has entered into a strategic partnership with Meituan’s drug...

Company Deals

Kangtai Biological Partners with Pakistani Firm for Pneumonia Vaccine Expansion

Fineline Cube Feb 17, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...

Posts pagination

1 … 613 614 615 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.